# Lucentis® (ranibizumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ranibizumab

> The FDA approved Lucentis® (ranibizumab), sponsored by AbbVie Inc. (ABBV), on August 2, 2022 for neovascular.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Lucentis® (ranibizumab) FDA approved?

Yes. The FDA approved Lucentis® (ranibizumab), sponsored by AbbVie Inc. (ABBV), on August 2, 2022 for neovascular. Press release filed with the SEC (EX-99): "CIMERLI (ranibizumab-eqrn), a Lucentis biosimilar, was approved by the FDA on August 2, 2022 for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization and we launched CIMERLI commercially in the United States on October 3, 2022." [Calendar and source filings](https://sec-api.dev/pdufa/ranibizumab)

Source: Press release filed with the SEC (EX-99), accession 0001104659-25-111484, https://www.sec.gov/Archives/edgar/data/1512762/000110465925111484/chrs-20251113xex99d1.htm (retrieved 2026-11-12). Last confirmed 2025-11-13. Cite: https://sec-api.dev/pdufa/ranibizumab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Lucentis® (ranibizumab) |
| Codes |  |
| Sponsor | AbbVie Inc. (ABBV) https://sec-api.dev/companies/abbv/catalysts |
| Indications | [neovascular](https://sec-api.dev/indications/neovascular), [Neovascular Age-Related Macular Degeneration (nAMD)](https://sec-api.dev/indications/neovascular-age-related-macular-degeneration-namd) |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### Aug 2021: topline data readout

- Status: completed, met. Date confidence: month. Stage: 3.
- First seen 2024-12-27, last confirmed 2024-12-27.
- SEC Form 10-K (accession 0001558370-24-016491): "NORSE TWO was our pivotal Phase 3 clinical trial comparing ONS-5010/LYTENAVA to ranibizumab (LUCENTIS) that reported highly statistically significant topline results in August 2021." https://www.sec.gov/Archives/edgar/data/1649989/000155837024016491/otlk-20240930x10k.htm

### August 2, 2022: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: neovascular.
- First seen 2025-11-13, last confirmed 2025-11-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-111484): "CIMERLI (ranibizumab-eqrn), a Lucentis biosimilar, was approved by the FDA on August 2, 2022 for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization and we launched CIMERLI commercially in the United States on October 3, 2022." https://www.sec.gov/Archives/edgar/data/1512762/000110465925111484/chrs-20251113xex99d1.htm

### August 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 2. Indication: Neovascular Age-Related Macular Degeneration (nAMD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04514653 (RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT04514653

### Aug to Nov 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Neovascular Age-Related Macular Degeneration (nAMD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04514653 (RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT04514653

### early 2027: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-11-09, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-072195): "Enrollment continues, and we anticipate initial data in early 2027." https://www.sec.gov/Archives/edgar/data/1360214/000162828026072195/hrow-20261109xlettertoshar.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-072195): "•TRIESENCE: A multicenter Phase 3 study evaluating TRIESENCE for the treatment of ocular inflammation and pain following cataract surgery continues to enroll, with initial data expected in early 2027." https://www.sec.gov/Archives/edgar/data/1360214/000162828026072195/hrow-20261109xpressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-072195): "Multicenter study evaluating TRIESENCE in ocular inflammation progressing, with initial data anticipated in early 2027 Next-Generation Product Candidate" https://www.sec.gov/Archives/edgar/data/1360214/000162828026072195/hrow-20261109xpresentati.htm

## Same indication

- [4d-150 ivt (3e10 vg/eye)](https://sec-api.dev/pdufa/4d-150-ivt-3e10-vg-eye) (FDMT)
- [PAVBLU® (aflibercept)](https://sec-api.dev/pdufa/aflibercept) (REGN)
- [Biosimilar](https://sec-api.dev/pdufa/biosimilar) (ALVO)
- [Eylea® (eylea)](https://sec-api.dev/pdufa/eylea) (REGN)
- [Otx-tki](https://sec-api.dev/pdufa/otx-tki) (OCUL)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ranibizumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lucentis® (ranibizumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ranibizumab

```bibtex
@misc{secapidev_pdufa_ranibizumab_20261116,
  title        = {Lucentis® (ranibizumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ranibizumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ranibizumab_20261116","title":"Lucentis® (ranibizumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ranibizumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
